# LYTENAVA

NDC: 82491-025
Generic name: bevacizumab-vikg
Labeler / Manufacturer: Outlook Therapeutics, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION
Routes: INTRAVITREAL
Marketing started: 20260716

FDA application: BLA761320

## Active ingredients

- BEVACIZUMAB: 1.25 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"82491-025"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=82491-025